Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
Eva De Smedt, Hui Lui, Ken Maes, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
Jing Liu, Ying Xie, Jing Guo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 61
Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1
Yuhong Lü, Yanfeng Liu, Sebastian Oeck, et al.
Molecular Cancer Research (2018) Vol. 16, Iss. 10, pp. 1458-1469
Open Access | Times Cited: 63
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Kenneth C. Anderson, Daniel Auclair, Stacey J. Adam, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 19, pp. 5195-5212
Open Access | Times Cited: 50
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Zonghui Ma, Andrew A. Bolinger, Haiying Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10991-11026
Open Access | Times Cited: 21
The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers
Wei-Xin Xu, Qiang Qu, Hai-Hui Zhuang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1652-1668
Open Access | Times Cited: 6
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?
Homa Fatma, Hifzur R. Siddique
Cancer and Metastasis Reviews (2023) Vol. 43, Iss. 1, pp. 423-440
Closed Access | Times Cited: 14
Methylation in cornea and corneal diseases: a systematic review
Yutong Xia, Kuangqi Chen, Qianjie Yang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Computational methods and next-generation sequencing approaches to analyze epigenetics data: Profiling of methods and applications
Itika Arora, Trygve O. Tollefsbol
Methods (2020) Vol. 187, pp. 92-103
Open Access | Times Cited: 39
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
Maria Serena Roca, Elena Di Gennaro, Alfredo Budillon
Journal of Clinical Medicine (2019) Vol. 8, Iss. 7, pp. 912-912
Open Access | Times Cited: 37
Targeting NF-κB Signaling for Multiple Myeloma
Ada Hang‐Heng Wong, Eun Myoung Shin, Vinay Tergaonkar, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2203-2203
Open Access | Times Cited: 34
Genome Instability in Multiple Myeloma: Facts and Factors
Anna Y. Aksenova, Anna S. Zhuk, Artem G. Lada, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 5949-5949
Open Access | Times Cited: 30
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death
Eva De Smedt, Julie Devin, Catharina Muylaert, et al.
Blood Advances (2021) Vol. 5, Iss. 9, pp. 2325-2338
Open Access | Times Cited: 28
Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
Elina Alaterre, Sara Ovejero, Laurie Herviou, et al.
Theranostics (2022) Vol. 12, Iss. 4, pp. 1715-1729
Open Access | Times Cited: 20
Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Federico Riccardi, Carmela Tangredi, Michele Dal Bo, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy
Yanmeng Wang, Niels Vandewalle, Kim De Veirman, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
Vincent G. Sorrentino, Srijan Thota, Edward A. Gonzalez, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 641-641
Open Access | Times Cited: 24
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse
Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Decoding DNA methylation in epigenetics of multiple myeloma
Ting Yang, Xiaobo Liu, Shaji Kumar, et al.
Blood Reviews (2021) Vol. 51, pp. 100872-100872
Closed Access | Times Cited: 22
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Tina Paradžik, Cecilia Bandini, Elisabetta Mereu, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1235-1235
Open Access | Times Cited: 21
Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
Assunta Melaccio, Antonia Reale, Ilaria Saltarella, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6491-6491
Open Access | Times Cited: 16
The Role of Epigenetics in the Development and Progression of Multiple Myeloma
Nor Hayati Ismail, Ali Mussa, Nur Atikah Zakaria, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2767-2767
Open Access | Times Cited: 15
Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
Laurie Herviou, Sara Ovejero, Fanny Izard, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 19
Targeted Therapies for Multiple Myeloma
Christopher Chang-Yew Leow, Michael Löw
Journal of Personalized Medicine (2021) Vol. 11, Iss. 5, pp. 334-334
Open Access | Times Cited: 16
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 12
Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
Jianbiao Zhou, Wee Joo Chng
Cells (2022) Vol. 11, Iss. 6, pp. 941-941
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top